ALCAM与VCAM-1作为系统性红斑狼疮活动性及长期肾脏结局的尿液生物标志物
研究纳入111例女性SLE患者和99例非SLE对照,检测尿sVCAM-1/肌酐和尿sALCAM/肌酐比值。结果显示两者在SLE患者中升高,且能区分活动性狼疮肾炎与静止期或无肾炎患者;基线尿sVCAM-1/肌酐比值≥75百分位的患者10年内eGFR下降≥25%的风险增加23倍。
要点
- 尿sVCAM-1/肌酐和尿sALCAM/肌酐在SLE患者中高于非SLE对照。
- 两者可区分活动性狼疮肾炎与静止期或无既往肾炎患者。
- 基线尿sVCAM-1/肌酐≥75百分位与10年eGFR下降≥25%风险增加相关。
核心结论
- 高尿sVCAM-1水平反映SLE疾病活动性,sALCAM可能在肾脏SLE中具有特殊重要性。
- 尿sVCAM-1和尿sALCAM均能区分活动性肾脏受累与静止期或无既往肾炎的SLE患者。
- 高尿sVCAM-1水平可能提示长期肾功能丧失风险增加。
研究设计与样本
- 纳入111例女性SLE患者和99例非SLE人群对照。
- 采用ELISA检测尿和血浆可溶性VCAM-1及尿sALCAM浓度,并用尿肌酐校正。
- 使用BILAG指数肾脏域评估肾脏活动性,随访10年观察eGFR变化。
主要发现
- 尿sVCAM-1/肌酐和尿sALCAM/肌酐比值在SLE患者中高于非SLE对照(两者P < 0.001)。
- 活动性/低活动性LN(BILAG A-C,n=11)患者尿sVCAM-1/肌酐和尿sALCAM/肌酐比值高于静止期LN(BILAG D,n=19)(分别P = 0.023和P = 0.001)。
- 有肾炎病史患者(BILAG A-D,n=30)尿sALCAM/肌酐比值高于无肾脏受累SLE患者(BILAG E,n=79)(P = 0.014),但尿sVCAM-1/肌酐比值无此差异。
- 基线尿sVCAM-1/肌酐比值≥75百分位的患者10年随访期间eGFR下降≥25%的风险增加(OR 22.9;95%CI 2.8, 189.2;P = 0.004),校正年龄、病程和器官损伤后仍显著。
- 传统标志物包括抗dsDNA抗体未能预测该结局。
关键数值与推荐
- 尿sVCAM-1/肌酐比值≥75百分位定义为高值,对应10年内eGFR下降≥25%的OR为22.9(95%CI 2.8, 189.2;P = 0.004)。
- 肾脏活动性采用BILAG肾脏域评分:A-C为活动性/低活动性,D为静止期,E为无肾脏受累。
临床怎么用
- 尿sVCAM-1/肌酐和尿sALCAM/肌酐可作为无创标志物辅助区分活动性狼疮肾炎与静止期或无肾炎患者。
- 基线尿sVCAM-1/肌酐≥75百分位提示长期肾功能下降高风险,可考虑加强监测。
- 抗dsDNA抗体未显示预测长期肾功能下降的能力,尿液标志物可能提供补充信息。
局限性
- 研究纳入的女性SLE患者样本量有限,活动性LN亚组仅11例。
- 对照组为非SLE人群,未包含其他肾脏疾病对照。
- 研究为观察性设计,尿液标志物的临床效用需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We investigated the cell adhesion molecules (CAMs) Vascular CAM 1 (VCAM-1) and Activated Leucocyte CAM (ALCAM) as urinary biomarkers in SLE patients with and without renal involvement. METHODS: Female SLE patients (n = 111) and non-SLE population-based controls (n = 99) were enrolled. We measured renal activity using the renal domain of the BILAG index and urine (U) and plasma (P) concentrations of soluble (s)VCAM 1 and U-sALCAM using ELISA. U-sCAM levels were next corrected by U-creatinine. RESULTS: U-sVCAM-1/creatinine and U-sALCAM/creatinine ratios were higher in SLE patients vs non-SLE controls (P < 0.001 for both), as well as in patients with active/low-active (BILAG A-C; n = 11) vs quiescent (BILAG D; n = 19) LN (P = 0.023 and P = 0.001, respectively). U-sALCAM/creatinine but not U-sVCAM-1/creatinine ratios were higher in patients with nephritis history (BILAG A-D; n = 30) vs non-renal SLE (BILAG E; n = 79) (P = 0.014). Patients with baseline U-sVCAM-1/creatinine ratios ≥75th percentile showed a 23-fold increased risk of a deterioration in estimated glomerular filtration rate by ≥25% during a 10-year follow-up (odds ratio: 22.9; 95% CI: 2.8, 189.2; P = 0.004); this association remained significant after adjustments for age, disease duration and organ damage. Traditional markers including anti-dsDNA antibodies did not predict this outcome. CONCLUSION: While high U-sVCAM-1 levels appear to reflect SLE disease activity, sALCAM might have particular importance in renal SLE. Both U-sVCAM-1 and U-sALCAM showed ability to distinguish SLE patients with active renal involvement from patients with quiescent or no prior nephritis. High U-sVCAM-1 levels may indicate patients at increased risk for long-term renal function loss.
引用
- Parodis I, Gokaraju S, Zickert A, et al. ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. Rheumatology (Oxford). 2020. PMID: 31722419. doi:10.1093/rheumatology/kez528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。